PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC). Here, we aimed to identify inhibitors that may enhance the anti-tumor acti...

Полное описание

Библиографические подробности

Главные авторы:	Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S. Lalani, Lisa D. Eli, Irmina Diala, Debu Tripathy, Bora Lim, Naoto T. Ueno
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2021-06-01
Серии:	Biomedicines
Предметы:	neratinib HER2-positive breast cancer triple-negative breast cancer RNAi screening synergistic effect
Online-ссылка:	https://www.mdpi.com/2227-9059/9/7/740
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!